CLOs on the Move

Idexx

www.idexx.com

 
IDEXX Laboratories, Inc. (NASDAQ: IDXX), a member of the S&P 500, is a leader in pet healthcare innovation, serving practicing veterinarians around the world with a broad range of diagnostic and information technology-based products and services. Headquartered in southern Maine, we conduct operations through more than 70 locations around the world and serves customers in over 175 countries. Our primary business focuses on pet health, a growing market around the world. Our products —in-clinic diagnostic tests and instrumentation, reference laboratory and telemedicine consultation services, and practice management software—enhance the ability of veterinarians to provide advanced medical care, improve staff efficiency and ...
  • Number of Employees: 1K-5K
  • Annual Revenue: > $1 Billion
  • www.idexx.com
  • One IDEXX Drive
    Westbrook, ME USA 04092
  • Phone: 207.856.0300

Executives

Name Title Contact Details
Rebecca Asen
 Associate General Counsel Profile
Lily Lu
 Vice President - Deputy General Counsel and Chief Compliance Officer Profile
Sharon Underberg
 Corporate Vice President, General Counsel, and Corporate Secretary Profile

Similar Companies

CBLPath

CBLPath is one of the leading companies in the Healthcare, Pharmaceuticals, & Biotech sector.

Columbia Orthopedic Group

Columbia Orthopedic Group is a Columbia, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Romark Laboratories LC

Romark Laboratories LC is a Tampa, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Jounce Therapeutics

Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long lasting benefits to patients through a biomarker-driven approach. Through the use of its Translational Science Platform, Jounce first focuses on specific cell types within the human tumor microenvironment to prioritize targets, and then identifies related biomarkers designed to match the right immunotherapy to the right patient. Jounce is developing two clinical-stage programs as well as advancing and building out its broad and wholly-owned discovery pipeline of immuno-oncology targets, including those expressed on T-regulatory cells, macrophages and stromal cells. Jounce`s lead product candidate, vopratelimab, is a monoclonal antibody that binds to and activates ICOS and is currently being assessed in a Phase 2 clinical trial. JTX-4014 is a PD-1 inhibitor intended for use in combination with future pipeline products, and Jounce has completed enrollment in the JTX-4014 Phase 1 clinical trial. In addition, Jounce has exclusively licensed worldwide rights to JTX-8064, a LILRB2 receptor antagonist, to Celgene. For more information, please visit www.jouncetx.com. We have many career opportunities at Jounce and are looking for exceptional individuals who share our passion and perseverance for developing highly durable cancer immunotherapies that can dramatically impact and improve patients` lives.

Cedar Court Imaging

Cedar Court Imaging is a Carbondale, IL-based company in the Healthcare, Pharmaceuticals, & Biotech sector.